MCM
RLAY icon

Moore Capital Management’s Relay Therapeutics RLAY Stock Holding History

Moore Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-130,162
Closed -$5.41M – 763
2020
Q4 		$5.41M Buy
+130,162
New +$5.88M 0.06% 223

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Moore Capital Management's RLAY Position: Q1 2021 in Review

Moore Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2021, closing a stake of 130,162 shares — an estimated $5.41M sold.

Moore Capital Management first reported a position in RLAY in Q4 2020 and held it in 1 quarter. The position peaked at $5.41M in Q4 2020. 137 funds tracked by Wall St. Rank hold RLAY as of Q1 2021.

  • Moore Capital Management reported no remaining Relay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 130,162 Relay Therapeutics shares in Q1 2021, an estimated $5.41M.
  • Moore Capital Management first reported a position in Relay Therapeutics in Q4 2020 and held it in 1 quarter.
  • Moore Capital Management's Relay Therapeutics position peaked at $5.41M in Q4 2020.
  • 137 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.